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Hyperferritinaemia is a common issue for clinicians and the associated diagnosis can often 
remain obscure particularly when the transferrin saturation is normal and HFE gene testing 
is not therefore the immediate route. Raised serum ferritin concentrations are not specific 
although they may represent iron overload (Worwood, 1990). A persistently raised ferritin 
without an immediate cause, for example inflammation, malignancy or hepatocyte damage, 
could signify one of several rare genetic disorders of iron metabolism. When investigating 
isolated hyperferritinaemia, ferroportin gene sequencing may be considered, particularly 
where there is evidence of Kupffer cell iron on biopsy and/or splenic iron overload on 
magnetic resonance imaging (MRI) (Pietrangelo, 2004). ‘Hereditary hyperferritinaemia 
cataract syndrome’ (HHCS) is a well-documented condition in which patients develop 
cataracts at an early age (Millonig et al, 2010). Inheritance is autosomal dominant, and 
substitution mutations in the IRE (iron response element) 5’ untranslated region (UTR) of 
the ferritin light chain (FTL) gene lead to unregulated synthesis of L-ferritin (Beaumont et al, 
1995). Cataracts are the only proven clinical manifestation of HHCS and are caused by 
accumulation of L-ferritin in the lens.  
Inherited hyperferritinaemia without any obvious clinical manifestations is only sparsely 
described in the literature. Three heterozygous mutations in exon 1 of the FTL gene have 
been associated with benign hyperferritinaemia where cataracts were absent. A case series 
was described where the p.(Thr30Ile) mutation was identified in a cohort of French families 
(Kannengiesser et al, 2009). Two further pathogenic mutations - p.(Ala27Val) and 
p.(Gln26Ile) - have been reported separately (Thurlow et al, 2012). These three mutations 
are associated with higher than normal serum ferritin glycosylation. With the advent of FTL 
gene testing, either directly or via a next generation approach, we sought to characterise all 
cases that have been identified in the UK with hyperferritinaemia specifically associated 
with these rare exon 1 mutations. 
Selected patients with unexplained hyperferritinaemia and normal transferrin saturation 
were investigated for the possibility of exon 1 mutations in the FTL gene (Cambridge and 
Oxford laboratories). C282Y homozygosity for HFE and ferroportin mutations had been 
excluded. 20 individuals, comprising 12 probands and 8 relatives (3 unaffected), underwent 
FTL promoter and exon 1 sequencing either directly or via a next generation approach (see 
online supplementary material). No patient had early cataracts and accordingly all 5’UTR 
sequences were wild-type. The 17 affected individuals associated with either one of the 
previously described p.(Thr30Ile) or p.(Ala27Val) mutations (Table 1). The cohort comprised 
9 males and 8 females (age range 20 to 68 years). All males had a serum ferritin >980mcg/L 
and mean ferritin values were 1163mcg/l in females and 2012mcg/l in males.    
9 of the 17 patients had hepatic iron content evaluated by MRI, with 8 demonstrating no 
evidence of iron overload (Table 1). The MRI of one patient (no. 9), a 38 year lean non-
drinking male, showed evidence of mild hepatic iron loading (2.9mg/g, normal range 
<1.2mg/g) - this subject was negative for all other known haemochromatosis-associated 
  
mutations via exome sequencing. A subsequent Fibroscan demonstrated no evidence of 
fibrosis (4.9kPa). Interestingly, the 68 year old father in this family (FTL_6) had 
haemochromatosis-type arthropathy on hand x-rays. No other affected individuals displayed 
any characteristic clinical signs or symptoms of iron overload. The heterozygous c.89C>T, 
p.(Thr30lle) mutation occurred in 3 families and 8 isolated individuals (Figure 1). The 
heterozygous c.80C>T, p.(Ala27Val) variant was present in a fourth family (FTL_6). Co-
segregation of the mutation was observed and inheritance was consistent with autosomal 
dominant transmission.  
8 of the 17 patients underwent therapeutic venesection in response to their 
hyperferritinaemia and 4 developed iatrogenic anaemia (Table 1). One patient (no. 11) 
developed symptomatic anaemia (Hb 81g/L from 144 g/L) following venesection. Only one 
patient (no. 17) underwent perhaps appropriate venesection as she was also a compound 
heterozygote (C282Y/H63D) for HFE. 
The p.(Thr30Ile) and p.(Ala27Val) pathogenic variants of the FTL gene are relatively rare 
findings each with only a single publication in the literature to date. The disorder is part of 
OMIM classification ‘hyperferritinaemia with or without cataracts’ (#600886). We found the 
p.(Thr30Ile) mutation explained the majority of cases. There was no evidence of iron 
overload in these individuals as in the French series of families with the same mutation 
(Kannengiesser et al, 2009). The p.(Ala27Val) variant was present in a single family (FTL_6) 
where all affected individuals had a serum ferritin of at least 2000mcg/L.  The male affected 
sibling had evidence of mild iron overload on MR imaging of the liver and his father was 
observed to have haemochromatosis-type arthropathy. Only one previous case of 
hyperferritinaemia associated with the p.(Ala27Val) mutation has been reported in the 
literature (Thurlow et al, 2012). The individual described did not appear to have any 
evidence of iron overload. 
Both mutations here affect positions in the ‘alpha’ helix near the N terminus of L-ferritin. It 
has been hypothesised that by increasing the hydrophobic cluster at the N terminus, 
hypersecretion of ferritin light chain ensues (Kannengiesser et al, 2009). It is not clear how 
iron overload might occur in this context, however, we observed a potential phenotype with 
the p.(Ala27Val) mutation. Of note, in silico analysis predicts a greater impact on protein 
function for p.(Ala27Val) compared with p.(Thr30Ile). 
In summary, we have characterised a UK cohort of patients with isolated hyperferritinaemia 
due to mutations in exon 1 of the FTL gene. We speculate there is a degree of genotype-
phenotype correlation within this limited pool of known FTL variants, p.(Ala27Val) possibly 
leading to iron loading whereas p.(Thr30Ile) would seem entirely benign. Only limited 
published data of ‘hereditary hyperferritinaemia without cataracts’ exist to date. It is 
important that clinicians are aware of this relatively novel syndrome when investigating 
patients with hyperferritinaemia and to incorporate FTL gene sequencing in their clinical 
algorithms (Cullis et al, 2018). Patients may be spared superfluous testing, delay in diagnosis 
  
and unnecessary venesection. Increased awareness of FTL gene testing should lead to ready 
diagnosis and expand our understanding of this hitherto poorly described disorder. 
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Table 1 
 
Characterization of affected cases with FTL gene exon 1 mutation 
 
Patient  Familial 
cluster 
Gender/age Mutation(s) Ferritin 
(mcg/L) 
 Tf sat IO signs MRI IO Venesected VIA 
1 FTL_1 M/35 FTL: p.Thr30Ile 1795 28% Nil No No n/a 
2 FTL_1 F/60 FTL: p.Thr30Ile 580 24% Nil n/a No n/a 
3 FTL_2 M/66 FTL: p.Thr30Ile 1500 n/a Nil No No n/a 
4 FTL_2 M/59 FTL: p.Thr30Ile 2405 n/a Nil No No n/a 
5 FTL_3 M/40 FTL: p.Thr30Ile 1335 n/a Nil No Yes Yes 
6 FTL_4 F/20 FTL: p.Thr30Ile 780 36% Nil No No n/a 
7 FTL_5 M/28 FTL: p.Thr30Ile 1384 44% Nil No Yes No 
8 FTL_6 M/68 FTL: Ala27Val 4500 11% Arthropathy n/a Yes Yes 
9 FTL_6 M/38 FTL: Ala27Val 2060 47% Nil Yes Yes No 
10 FTL_6 F/41 FTL: Ala27Val 2000 46% Nil n/a Yes No 
11 FTL_7 F/61 FTL: p.Thr30Ile 1861 39% Nil No Yes Yes 
12 FTL_7 F/60 FTL: p.Thr30Ile 1095 28% Nil No Yes Yes 
13 FTL_8 F/46 FTL: p.Thr30Ile 800 30% Nil n/a No n/a 
14 FTL_9 M/37 FTL: p.Thr30Ile 980 39% Nil n/a No n/a 
15 FTL_10 F/58 FTL: p.Thr30Ile 789 13% Nil n/a No n/a 
16 FTL_11 M/51 FTL: p.Thr30Ile 2152 24% Nil n/a No n/a 
17 FTL_12 F/67 FTL: p.Thr30Ile 
HFE:C282Y/H63D 
1400 36% Nil n/a Yes No 
 
Key:  
Tf sat = transferrin saturation 
IO = iron overload 
VIA = venesection induced anaemia 
 
 
  
Figure 1 
 
Families characterised with and without FTL variants in the study cohort  
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   Fer = ferritin 
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